HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $170 to $221.